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Executive Summary 
 
Fentanyl is an analgesic that is about 80 times more potent than morphine. It is administered as 
a transdermal patch for chronic pain relief and as an oral transmucosal lozenge for 
breakthrough pain relief which is often experienced by cancer patients. The latter 
administration, under the brand Actiq® exploits the higher permeability of buccal mucosa to 
achieve a much faster onset. We developed a model of a transmucosal patch as an alternative to 
existing designs, in order to achieve faster pain relief, improved dosage efficiency, and greater 
pharmacokinetic control via an impermeable layer. We simplified the design in to 1D model 
with diffusion and a reaction rate, which simulates uptake fentanyl into the blood. After 
implementing the model in COMSOL, we calculated the pharmacokinetic profile of fentanyl in 
the plasma over time with first order linear non homogenous equation. Our resultant profile 
peaks at 20 minutes and matches Actiq®’s profile. A sensitivity analysis yielded that the 
plasma elimination rate of fentanyl, the epithelium diffusivity and the diffusivity, thickness and 
distance of the impermeable layer all had a significant affect on the time to peak. A second 
sensitivity analysis determined that the initial concentration and diffusivity, thickness and 
distance of the impermeable layer had the greatest influence on peak fentanyl concentration. In 
conclusion, we believe that a transmucosal patch is a viable design alternative for fentanyl 
delivery due to it’s a rapid onset and the potential for diffusive control with the impermeable 
layer. Further exploration is recommended to evaluate   
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Introduction 
 
Fentanyl is an analgesic that is about 80 times more potent than morphine, and shows great 
promise for fast-acting severe pain relief. Fentanyl is effective at plasma concentrations as low 
as 2ng/ml and undergoes rapid metabolism. It is commercially available as a transdermal patch 
and as an oral transmucosal lozenge under the names Duragesic® and Actiq® (Fig. 0), 
respectively. The transdermal patch focuses to relieve chronic pain, and therefore has a delayed 
effect which results in the accumulation of Fentanyl in the skin. Transmucosal delivery avoids 
these problems because of the higher 
permeability of the buccal mucosa as 
compared to the skin, yielding a 15-20 
minute onset in Actiq®. Actiq® is 
primarily intended for breakthrough 
cancer pain relief, in which patients have 
developed considerable tolerance to 
existing analgesics. Despite Actiq®’s 
advantages, the lozenge delivery is 
poorly controlled as 75% of Fentanyl is 
lost to saliva. Since Actiq® is 
administered as a lozenge, the drug 
delivery is not easily controlled by the 
doctor. Additionally, the drug delivery is 
affected by changes in pH, temperature, 
and the amount of saliva. For this 
reason, we wish to model a 
mucoadhesive Fentanyl patch in order to 
obtain better pain relief, with greater 
efficiency and control.  
 
 
Design Objectives 
 
The purpose of our model is to evaluate the potential of a fentanyl transmucosal mucoadhesive 
patch as an alternative to the already existing transdermal patches and oral transmucosal 
lozenges. Our first design objective is to decrease the time for fentanyl to reach effective 
plasma concentrations. Faster delivery of Fentanyl would result in faster pain relief, which is a 
top priority among breakthrough cancer patients. As a result, patients would be able to 
conveniently obtain pain relief as necessary, without the need for sustained analgesic 
concentration in the plasma. Our second design objective is to increase the effective fentanyl 
plasma concentration for a given dosage. This objective aims to be a direct improvement on the 
75% mass inefficiency of Actiq®. In addition, we anticipate an adhered patch would be less 
susceptible to the oral cavity uncertainties in temperature, pH, and amount of saliva, therefore 
improving overall control. Our final design objective is to determine the influence of an 
impermeable layer within the patch that can be used to control the diffusion of fentanyl. If we 
can manipulate the diffusivity or distance of the impermeable membrane to the tissue, we can 
Figure 0. Actiq® lollipop. 
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customize the pharmacokinetic profile without changing the concentration of fentanyl within 
the patch. 
 
Problem Schematic 
 
The cheeks of the oral cavity are lined with the buccal mucosa, see 
Fig. 1. The stratified squamous epithelium of the buccal mucosa is 
not keratinized. Keratinized epithelium contains lipids which 
significantly impede the layer’s permeability to water and water 
soluble compounds. As a result, the buccal epithelium is more 
permeable than the epidermis and other keratinized epithelia. 
Underneath the epithelium is a think layer called the lamina 
properia. The buccal submucosa lies underneath the epithelium 
and lamina properia, and is rich in blood vessels. 
 
 
 
 
 
 
Figure 2. Schematic of the patch, mucosa and their various dimensions. 
 
A schematic of our proposed model of the transmucosal drug delivery is shown in Fig. 2. 
Fentanyl diffuses from the patch, through the epithelium and into the submucosa, where is 
enters systemic circulation. We chose to simplify our model by combining the lamina and 
submucosa because the geometry of the lamina was difficult to model and has very similar 
diffusive properties to the submucosa. The diameter of the cylindrical patch is 2cm, with a 
height of 0.5mm. The epithelium and submucosa are 0.1mm and 3mm respectively. In addition 
to the adhesive patch, epithelium and submucosa, we incorporate a 0.2mm impermeable 
membrane in the patch to examine the effect of controlled diffusion. Because the flow of 
fentanyl is predominately from the patch to the submucosa, we used a 1D model 
(experimentation with a 2D axi-symmetrical model is shown in the appendix). We modeled the 
mass diffusion of fentanyl taking into consideration the transient, diffusion and reaction terms 
as shown below: 
R
x
c
D
t
c
2
2
    (1) 
Figure 1. Schematic showing 
epithelium, lamina properia, 
and submucosa. 
6 
 
 
where c is the concentration of fentanyl, D is the diffusivity of the layer and R is the reaction 
rate of fentanyl in the layer.  
 
The diffusivity of mucoadhesive hydrogel patches is typically 10
-7 
m
2
/s. In the presence of the 
impermeable layer, the diffusivity is changed to 10
-11
 m
2
/s. Studies have shown that the 
diffusivities of the buccal mucosa epithelium and submucosa are 4*10-11 and 10-11 m2/s 
respectively. The purpose of the reaction rate is to model the uptake of fentanyl into blood. 
Uptake of drugs into blood vessels is often modeled by 1
st
 order reaction rates, with a reaction 
coefficient of ~1 for highly vascularized tissue, such as the submucosa. In order to approximate 
the complicated geometry of the epithelium and lamina properia, we included a reaction rate in 
the epithelium, albeit only 10% of the rate in the submucosa.  
 
0PatchR   cREpithelium 1.0   cR aSubmucos   (3) 
 
Since source and sink of fentanyl is the patch and the submucosa respectively, we treat our 
model as an isolated system. Our boundary conditions on the top of the patch and the bottom of 
the submucosa are both zero flux. 
 
00,xPatch
x
c
 and 0003.,cos xaSubmu
x
c
  (2) 
 
Actiq® is currently available in 200, 400, 600, 800, 1200 and 1600μg dosages. Given that the 
volume of our patch is 1.57 * 10
-7
m
3
 and fentanyl’s molecular weight of 336g/mol, we can 
calculate our initial molar mass to match Actiq®’s dosages. Since we expect our patch to use 
less fentanyl than Actiq®, we chose an initial mass of fentanyl in our patch of 5 mol/m3, 
corresponding to ~250μg dose. 
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Results 
 
In order to achieve our design objectives we modeled the system in COMSOL (details in 
appendices), a finite element approach to modeling diffusive processes. Initially, the system 
only modeled the concentration of drug in the patch and tissue layers.  However, this resulted in 
a simple solution where over time the drug reached a uniform concentration in the tissue. 
However, the submucosa (and to some extent the epithelium) is highly vascularized, and would 
quickly take up the fentanyl as it was diffusing.  Therefore, a reaction rate in the submucosa 
(and a smaller reaction rate in the epithelium) was added to simulate uptake to the blood. 
 
However, it is actually the concentration of fentanyl in the blood that is of interest.  
Pharmacokinetic data (and intuition) point to the fact that concentration in the blood 
approaches zero over time as the drug is metabolized and systemically removed.  To accurately 
replicate this data, a first order differential equation was solved in COMSOL.  This equation 
included terms that represented drug uptake to the blood and clearance/metabolism of drug in 
the blood.  This is shown below. 
 
 
 
 
        =  
 
 
 
 
The most apparent characteristics of the drug profile are the brief burst immediately following 
administration and the tapering tail following the burst.  With our default values we achieved a 
peak time of 20min and a concentration of Fentanyl of 0.09 ng/mL (see Fig. 3). Depending on 
the dosage administered in the patch, the peak concentration in the burst increases 
proportionally.  This peak is desirable because it provides pain relief to the patient by after only 
a few minutes.  Once the drug concentration in the blood spikes, the patient receives pain relief 
and the tapering drug concentration will sustain the patient for several more hours. 
__ 
Rate of change of 
fentanyl plasma 
concentration: dc/dt 
(mol/mL)  
 
Rate of change of fentanyl 
plasma concentration due to 
adsorption: f’ 
(derivative of output) 
Rate of change of fentanyl 
plasma concentration due to 
elimination: k ∙ c 
(1st order reaction rate)  
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Figure 3. Drug concentration profile for varying initial concentrations (5, 10, 15 mol/m^3 
corresponding to triangles, squares, and circles respectively). 
Finally, Fig. 4 shows our final drug profile across the patch.  The scale of the y-axis is 
extremely small, indicating that after 50000 seconds (13.9 hours), there is essentially no drug 
left in the patch.  This is excellent, because it indicates that little or no drug is left in the patch.  
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Figure 4. COMSOL model after t=50000s (13.9hrs). Note that the total concentration of the drug 
left in the system is nearly zero, this is because it has all been wicked away by the blood (as 
modeled by the reaction constant). 
 
Sensitivity Analysis 
 
In evaluating our model, several parameters were identified as candidates for sensitivity 
analysis based on their significance in the model formulation.  These parameters include: 
 Diffusivity of the epithelium 
 Reaction rate in the submucosa 
 Reaction rate in the epithelium 
 Clearance rate (elimination rate constant) in the blood 
 Initial Concentration 
 Diffusivity of the impermeable layer 
 Thickness of the impermeable layer 
 Location of the impermeable layer in relation to the epithelium 
These eight parameters were evaluated on their impact on two metrics: time to peak blood 
concentration and peak blood concentration itself.  Results from the sensitivity analysis are 
shown in Fig. 5 and Fig. 6.  In each case, the parameter being evaluated was increased and 
decreased by 20% of its initial value.  The sensitivity analysis considered two types of 
parameters: design parameters (those relating to the qualities of the patch, such as barrier 
diffusivity) and system parameters (those relating to the qualities of the patient, such as 
epithelial diffusivity). 
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Time to peak concentration is the more important of the two metrics because it directly 
determines how quickly patients experience pain relief.  The three system parameters that affect 
time to peak concentration most significantly are clearance rate in the blood, epithelium 
reaction rate, and diffusivity in the epithelium.  Qualitatively, it makes sense that these three 
parameters would have an impact on time to peak concentration.  Changes in clearance rate in 
the blood determine how quickly blood can eliminate drug that accumulates systemically in the 
body.  Lower clearance rates imply that more of the drug can accumulate before the rate of 
clearance overcomes the rate of accumulation, and so lower clearance rates yield higher time 
for peak concentration (and higher clearance rates yield smaller time to peak concentration).   
 
Similarly, the reaction rate and diffusivity in the epithelial layer influence the time to peak 
blood concentration.  This is an intuitive result: the epithelial layer acts as the primary barrier to 
diffusion of the drug into the submucosa (where most of the drug is taken up into the blood).  
Thus, reducing the time that drug resides in the epithelial layer as well as increasing the amount 
that is taken up in this layer, will increase the rate at which drug reaches the blood. 
 
 
Figure 5. Sensitivity analysis plot for important system variables, and their effect on time 
to peak. Each variable was tested at +/- 20% of the default value, and results are shown as 
percent change from the default time to peak. 
A large effect was also observed as our three system parameters were altered.  These results are 
critical, as they indicate that the time to peak may be controlled by the design of our 
impermeable barrier.  The parameter which had the greatest affect on time to peak 
concentration was distance of the patch barrier from the epithelium.  This is an extremely 
desirable result, because in terms of manufacturing difficulty, the parameter which is easiest to 
modify is the placement of our patch barrier.  By increasing the distance between the barrier 
and the skin, we can reduce the time to peak concentration.  Similarly, by the reducing the 
distance, we can increase the time.  In addition, the thickness of the barrier has an effect on 
time to peak concentration.  Increased thickness prolongs the time to peak, while decreased 
thickness reduces the time to peak. 
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The actual peak concentration is another metric we used in our sensitivity analysis. Initial 
concentration has the single greatest impact on actual peak concentration, but this is expected 
as increasing the dosage will naturally increase the peak blood concentration.  None of the 
other parameters tested seemed to significantly affect the actual peak concentration.  Aside 
from the clearance rate, the rest of the parameters relate to the rate of flow of drug into the 
blood, rather than the amount of drug itself.  Thus, it is expected that these parameters would 
affect time to peak concentration more than actual peak concentration. 
 
Figure 6. Sensitivity analysis plot for important system variables, and their effect on peak 
concentration. Each variable was tested at +/- 20% of the default value, and results are 
shown as percent change from the default peak concentration. 
The system parameter that affected the peak concentration most significantly was the thickness 
of the patch barrier.  As the patch barrier’s thickness is reduced, a smoother, more constant 
blood concentration profile is achieved.  Conversely, if the barrier’s thickness is increased, a 
sharper blood concentration profile with a more pronounced peak is produced. 
 
Addition of a Diffusive Barrier in the Patch 
 
In order to custom tailor the curve of the patch we considered adding a barrier with a lower 
diffusivity inside the patch. As seen in Fig. 7, addition of this layer reduces the peak value, 
increases time to peak, and reduces the steepness of the curve.  While these results may 
contradict our initial objectives of increasing time to peak and the peak concentration, they 
provide important information for future designs.  The ability to alter the shape of the blood 
concentration profile adds a significant amount of control over how the drug is administered.  
By decreasing the peak concentration, greater dosages can be administered and higher 
concentrations can be maintained, for prolonged periods without resulting in patient overdose. 
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Figure 7. Profile with patch barrier (triangles) and without (circles). 
 
Qualitative Interpretation 
 
As the simulation starts the drug diffuses from the patch and into the epithelial layer.  This 
layer has the lowest diffusivity of all layers in the system, and therefore serves as the rate-
limiting layer in the process of drug absorption.  As diffusion brings the drug into the 
submucosa, uptake to the blood occurs in both the epithelium and submucosa.  Once in the 
blood, the drug is subject to a first order elimination reaction.  Both the concentration and 
elimination rate of the drug increase until the peak concentration value is reached.  The 
concentration steadily declines thereafter due to a reduced amount of drug left in the patch and 
a correspondingly high elimination rate.  The result is the concentration profile with a peak 
immediately following administration and then a long tapering tail. 
 
Discussion on Realistic Constraints 
 
Our model was designed to simulate a buccal mucosal patch for the administration of fentanyl.  
In accordance with our design objectives, we sought to deliver the drug quickly to the patient 
and efficiently (without loss of drug to systemic metabolism).  In this way, we could provide 
immediate relief to the patient and eliminate waste from administered dosages. 
 
In this context, there are several issues to discuss relating to the implementation of our design.  
Because fentanyl is intended for patients with extremely severe chronic pain, it is a benefit that 
our blood profiles exhibit a characteristic shape of an immediate peak followed by a long, 
gradual decay.  In this way, patients receive a quick burst of relief that will help them overcome 
a burst of pain and sustain them for several hours.  Unlike other drugs, the tapering effect 
13 
 
reduces the likelihood that patients will abuse our patch because they will only experience a 
brief “high.”   
 
From a manufacturing standpoint, our mechanism of delivery offers a more efficient method 
for administering drug to a patient.  Data from the current formulation of Actiq® estimates that 
75% of drug is lost to the saliva.  However, the buccal mucosal patch is adhesive and prevents a 
great deal of salivary loss.  Thus, less of the drug needs to be included in the same formulation 
in order to trigger the same response in the patient. 
 
In addition, the implementation of a low diffusivity layer can alter the blood concentration 
profile.  This could allow the drug to remain in the system longer without risking the health of 
the patient.  This also enables physicians to customize their prescriptions based on a patient’s 
particular qualities and needs.  Such customization and precise control is not possible with the 
current Actiq® lozenge.  
 
Conclusion and Recommendations 
 
From the results of our model, it is reasonable to conclude that a buccal mucosal patch is a 
viable alternative to current products for delivery of fentanyl.  In comparison to the current 
Actiq® delivery system, our patch reduces drug loss to the saliva and is a hands-free alternative 
to a lozenge. Conversely, our design faces several challenges.  First, it may be uncomfortable to 
some patients.  Secondly, since only computer simulations have been completed to date, no 
method of adhesion to the buccal mucosa has yet been determined.   
 
Using our computer simulation as a guide, we plan to use experimentation and clinical trials to 
definitively assess the viability of our design.  Our sensitivity analysis will be essential in 
steering experiments towards the optimal design by highlighting the most sensitive and 
significant parameters.  Finally, experiments will clarify how assumptions made in the model 
actually affect the final results. 
 
Based on our results and corresponding sensitivity analysis, we now have a better idea of the 
most significant parameters of our design.  Keeping this in mind, we suggest designing the 
patch with an array of high diffusivity barbs that could increase the rate of the initial rise in 
concentration.  By bypassing the layer of lowest diffusivity, the drug can be diffuse into the 
submucosa faster, and therefore be taken up into the blood faster.  When dealing with 
breakthrough cancer pain, the rate at which pain relief occurs is a vital aspect.  It has also been 
shown that applying heat to the patch and surrounding tissue could increase diffusivity, so 
perhaps recommending that patients consume hot tea after placing the patch in their mouth 
would also increase drug efficacy. 
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Appendices: 
 
 
APPENDIX A:  Values Used 
 
Detailed diagram, governing equations, boundary conditions, and initial conditions provided in 
the problem schematic section earlier. Below is a table detailing system parameters along with 
sources used to find them.  
 
Parameter patch 
impermeable 
membrane epithelium submucosa 
Initial Concentration 5 mol/m3 5 mol/m3 0 mol/m3 0 mol/m3 
Source Calculations shown below 
Diffusivity 10^-7 m2/s 10^-11 m2/s 4*10^-11 m2/s 10^-11 m2/s 
Source 7-9 7-9 7-9 7-9 
Reaction Rate 
Coefficient 0 0 -0.1 -1 
Source 7-9 7-9 7-9 7-9 
Table A1 
 
The initial concentration of our patch was based on the Actiq® dosages. We used a default 
dosage of ~250μg, which can be calculated to be 5 mol/m3 using fentanyl’s molecular weight of 
36g/mol and our patch volume of 1.57 * 10-7m3.  
 
 
Other Parameters Values Source 
Plasma volume 2.7 L  
elimination rate constant 0.0003 5 
Table A2 
 
 
dimensions thickness 
patch above 
membrane 0.15 mm 
impermeable 
membrane 0.2 mm 
patch below 
membrane 0.15 mm 
epithelium 0.1 mm 
submucosa 3 mm 
Table A3 
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APPENDIX B: Computational Methods 
 
 
Initially we modeled the system using a 2D axis-symmetric model, Fig. A1, and showed that it 
could be accurately represented by a much simpler 1D model, mesh shown in Fig. A2.  The 2D 
axis-symmetric model consisted of our patch, impermeable layer, epithelium and the 
submucosa, all with equivalent depth and diffusivities to our current model.  The epithelium 
and submucosa that was modeled had a radius twice that of the patch.  We found upon running 
the simulation that diffusion in the radial direction was negligible and the system could be 
treated as a 1 dimensional model. 
 
 
 
 
 
 
The 1D model we implemented in COMSOL consisted of a non-uniform mesh with a minimum 
element size of 0.000001m in the most critical region with a mesh element growth rate of 1.1 
(see plot below).  
 
 
Figure A2. Nonlinear mesh of the model system, dimensions in meters. 
 
Using COMSOL’s finite element method with a time step of 5 seconds we solved the 
governing equations with the associated boundary conditions discussed above. The tolerance 
was 0.01 and the absolute tolerance was set to 0.001 (the default values). In order to solve for 
the pharmacokinetic drug profile shown in the results we used COMSOL to integrate a 
differential equation based on the diffusion model and a first order reaction rate as described in  
the results section.  
 
 
 
 
 
Figure A1. 2D and 1D computational models after being run in COMSOL. 
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Mesh Convergence 
 
In order to test the accuracy of our mesh, we did a mesh convergence analysis using constant 
mesh sizes, shown in Fig. A3. We chose to check the time of the peak concentration, as that is 
the value we are most interested in. Due to the complicated dynamics of this nonlinear system 
the mesh convergence oscillates a few times before settling down. In order to dramatically 
reduce the computation time that would be required to achieve accurate results we used a 
nonlinear mesh, where the elements are smallest in the most critical areas. Around the 
epithelium layer we have a minimum mesh size of 0.000001m and a growth rate of 1.1. This 
resulted in accurate mesh convergence (as seen by the pink square in our plot), with a total of 
only 198 mesh elements. Due to our simplified linear model, we are able to get accurate results 
with very short simulation times.  Based on the mesh convergence results we can conclude that 
our results are independent of the mesh characteristics.  
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Figure A3. Mesh convergence plot. Note the oscillations before the mesh finally converges 
after 25,000 elements. Using a non-uniform mesh of 198 elements we were able to achieve 
similar accuracy in much less time. 
Accuracy Check 
 
In order to check the accuracy of our model we compared the results to the experimental results 
published by Actiq®, reproduced in Fig. A4, which uses the same active ingredient fentanyl. 
The Actiq® approach consists of a lollipop impregnated with the drug that the patient puts in 
their mouth until they get the desired pain relief. In Fig. A4 the effect of the drug is seen for 
various dosages. In our model we plotted the concentration profile in the blood over time for 
initial concentrations equal to 5, 10, and 15 mol/m
3
, as seen earlier in Fig. 3. 
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While the exact concentrations do not entirely match, the general shape of the curve is the 
same, and the peak times and values are within an order of magnitude of the Actiq® system. 
The two systems are different, so one would expect there to be some discrepancies. The 
similarities, however, suggest that our model should be within the range that we can begin 
doing conservative, careful clinical trials to further validate its accuracy.  
 
 
 
 
 
Figure A4. Drug concentration profiles for varying dosages of Actiq®, adapted from Actiq.com 
Table A4. Comparison of drug 
dosages and equivalent initial 
concentrations for our patch 
based on our patch volume (see 
diagram). 
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